Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02899221 · ClinicalTrials.gov registry record · NA

Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation

A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

Completed
Registry status
NA
Development phase
3
Enrollment target

NCT02899221: Completed NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

NCT02899221 is a NA study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02899221, a NA study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

COMPLETED
Registry status
NA
Development phase
3 participants
Enrollment target

Study Summary

This phase I trial studies the side effects and best way to give hyperthermia and high dose rate radiation therapy in treating patients with prostate cancer that has come back after prior radiation treatment. Radiation therapy, such as high dose rate brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Hyperthermia therapy may make tumor cells more sensitive to the effects of radiation therapy by heating them to several degrees above normal body temperature. Giving hyperthermia and high dose rate radiation therapy may work better in treating patients with recurrent prostate cancer after radiation.

Primary Outcome

Will be computed with the corresponding 90% exact binomial confidence intervals.

Interventions

  • OTHER Laboratory Biomarker Analysis
  • RADIATION High-Dose Rate Brachytherapy
  • PROCEDURE Hyperthermia Treatment

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2017-03-21
Est. Completion 2025-10-29
Phase NA

What the finished NCT02899221 record still lists

NCT02899221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02899221 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02899221 about?

NCT02899221 is a clinical study titled "Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation". This phase I trial studies the side effects and best way to give hyperthermia and high dose rate radiation therapy in treating patients with prostate cancer that has come back after prior radiation treatment. Radiation therapy, such as high dose rate brachytherapy, uses radioactive material placed d...

What is the current status of trial NCT02899221?

This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2017-03-21. Estimated completion is 2025-10-29.

What interventions are being tested in trial NCT02899221?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), High-Dose Rate Brachytherapy (RADIATION), Hyperthermia Treatment (PROCEDURE).

Who is sponsoring clinical trial NCT02899221?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02899221's enrollment target sits among peer trials

3 1996th of 2000 higher than 4 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02899221, the US trial registry maintained by the National Library of Medicine. NCT02899221 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.